Fig. 5: c-Myc is required for ZMYND8-induced trastuzumab resistance.
From: ZMYND8 drives HER2 antibody resistance in breast cancer via lipid control of IL-27
a Immunoblot analysis of c-Myc and ZMYND8 proteins in parental, ZMYND8 KO1 and ZMYND8 KO1+c-Myc HR6 cells (n = 3). b, c Clonogenic growth of parental, ZMYND8 KO1 and ZMYND8 KO1+c-Myc HR6 cells treated with vehicle or trastuzumab for 6 days. Representative colony images (b) and quantification (c, n = 3). d Immunoblot analysis of ZMYND8 and c-Myc in parental, c-Myc KO1, and c-Myc KO1 + ZMYND8 HR6 cells (n = 2). e, f Clonogenic growth of parental, c-Myc KO1, and c-Myc KO1 + ZMYND8 HR6 cells treated with vehicle or trastuzumab for 6 days. Representative colony images (e) and quantification (f, n = 2). g, h Growth of parental, ZMYND8 KO1 and ZMYND8 KO1+c-Myc HR6 tumors in mice treated with vehicle or trastuzumab. Tumor growth curve (g) and the percentage of tumor inhibition (h, n = 5). Data from biological replicates represent mean ± SEM. P-value was determined by one-way ANOVA with Dunnett’s test (h) or two-way ANOVA with Tukey’s test (c and g). Source data are provided as a Source Data file.
